Shaking Off US Rebuff, Gilead And Galapagos Get Filgotinib Green Lights In EU And Japan

Galapagos and Gilead's JAK inhibitor has been approved for rheumatoid arthritis in the second and third biggest pharma markets, softening the blow somewhat of rejection from the US FDA in the biggest market last month.